Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Bullboard Posts
Comment by Thisisfunstuffon May 14, 2019 6:17pm
125 Views
Post# 29747175

RE:RE:RE:Stifel Nicolaus

RE:RE:RE:Stifel Nicolaus

Equities research analysts at Stifel Nicolaus started coverage on shares of Theratechnologies (TSE:TH) in a research report issued on Tuesday, TipRanks reports. The brokerage set a “buy” rating and a C$15.00 price target on the stock. Stifel Nicolaus’ price target suggests a potential upside of 138.85% from the company’s previous close.

Several other brokerages have also recently issued reports on TH. Echelon Wealth Partners reaffirmed a “buy” rating on shares of Theratechnologies in a report on Friday, February 22nd. Royal Bank of Canada decreased their price objective on Theratechnologies from C$12.00 to C$10.00 and set a “sector perform” rating on the stock in a report on Friday, February 22nd. Finally, National Bank Financial decreased their price objective on Theratechnologies from C$12.00 to C$11.25 and set an “outperform” rating on the stock in a report on Friday, April 5th.

Bullboard Posts